EPM
DFTX

Equitec Proprietary Markets’s Definium Therapeutics DFTX Stock Holding History

Equitec Proprietary Markets’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,400
Closed -$15K – 225
2022
Q3 		$15K Buy
+4,400
New +$42.2K ﹤0.01% 172

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Equitec Proprietary Markets's DFTX Position: Q4 2022 in Review

Equitec Proprietary Markets sold out of Definium Therapeutics (DFTX) in Q4 2022, closing a stake of 4,400 shares — an estimated $15K sold.

Equitec Proprietary Markets first reported a position in DFTX in Q3 2022 and held it in 1 quarter. The position peaked at $15K in Q3 2022. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

  • Equitec Proprietary Markets reported no remaining Definium Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Equitec Proprietary Markets sold 4,400 Definium Therapeutics shares in Q4 2022, an estimated $15K.
  • Equitec Proprietary Markets first reported a position in Definium Therapeutics in Q3 2022 and held it in 1 quarter.
  • Equitec Proprietary Markets's Definium Therapeutics position peaked at $15K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on Equitec Proprietary Markets's 13F filing for Q4 2022, filed 31 Jan 2023.